03 maj: Ørsted indfører aktiebaserede fastholdelsesaftaler til udvalgte m..
03 maj: Conferize A/S udsteder warrants
03-05-2018 12:04:03

Coloplast delivers 8% organic revenue growth and upgrades full-year growth expectations

Relateret indhold
11 jul - 
Onsdagens aktier: Pandora funklede og Mærsk snublede i ..
11 jul - 
Aktier/middag: Mærsk i bølgegang efter intensivering af..
11 jul - 
Aktier/åbning: Mærsk rammer bunden i rødt C25 efter nyt..
Relateret debat
12 jul - 
Det med analytikere.. Sad selv i aktieafdelingen i en a..
12 jul - 
Næ… det er da rigtigt nok, så l&aeli..
12 jul - 
Tillykke til dem med prisen. Dejligt med en form for be..

Coloplast delivered 8% organic revenue growth and a 31% EBIT margin at constant exchange rates in the first six months of its 2017/18 financial year. For the full year 2017/18, the company now guides 7-8% organic revenue growth from previously ~7%, and reported growth in DKK of ~6% from previously 5-6%.

Coloplast delivered 8% organic revenue growth in the second quarter of its financial year, while reported revenue in DKK was up by 4% to DKK 4,035m. The H1 organic revenue growth was also 8%, while reported revenue in DKK was up by 5% to DKK 7,990m. Reported revenue was adversely affected by the depreciation of USD and dollar-related currencies against DKK.

EBIT amounted to DKK 2,407m for a 3% decline in DKK but a 4% increase at constant exchange rates. The EBIT margin at constant exchange rates was 31% against 32% in the same period last year. In DKK, the EBIT margin was 30%, against 32% last year. The EBIT result is in line with the company’s expectations.

  • “We deliver a strong half-year result with solid growth across our chronic care business and an increased momentum in our emerging markets. At the same time, the SpeediCath® patent expiry has had a smaller impact than initially anticipated. This allows us to upgrade our full-year growth expectations, which I’m obviously very pleased with,” said Coloplast President and CEO Lars Rasmussen. 

Organic growth rates by business area: Ostomy Care 10%, Continence Care 9%, Urology Care 10%, and Wound & Skin Care negative 1%. The wound care business accelerated its momentum, delivering 8% organic growth in the second quarter despite the continued negative effects of a comprehensive pricing reform in Greece.

  • “We’re expanding our ostomy care product portfolio by introducing SenSura® Mio Concave, designed specifically for the outward body profile and customized to help stoma patients avoid leakage. It will be part of the same portfolio as SenSura® Mio Convex, the company’s most successful launch to date. As a result, we have very high expectations for the new product category, SenSura® Mio Concave, which is now available and eligible for reimbursement in seven countries,” said Mr Rasmussen.

Looking at sales by geographies, the European markets contributed with 4% growth in H1, Other developed markets delivered 13% revenue growth, while Emerging Markets provided a 16% increase.

Tailwind and growth ambitions in the US

As part of the plan to accelerate organic growth in the US market, Coloplast has appointed Manu Varma as Senior Vice President of Chronic Care North America. Former Senior Vice President Ed Veome will take on a new role as Vice President of Sales of Chronic Care North America.

  • “The US market holds great potential, and our ambition is to continue to take market share. To that end, we are investing to accelerate growth, which includes investing in and expanding our North American leadership team,” said Mr Rasmussen.

Coloplast is also expanding its continence care and wound care product portfolios in the US market by launching the SpeediCath® Flex Coudé Pro, specifically designed for the US market, and the entire Biatain® Silicone portfolio.

In addition, Coloplast has been chosen as the primary ostomy care vendor at Cleveland Clinic, one of the leading hospital chains in the USA. Coloplast will be the new main supplier of ostomy care products to all Cleveland Clinic hospitals. 

Financial guidance 2017/18

Coloplast now guides 7-8% organic revenue growth, up from previously ~7%, at constant exchange rates. The change is primarily due to expectations that the patent expiry of SpeediCath® standard catheters will have a negative effect of DKK 50m instead of the previous estimate of DKK 100m and due to increased momentum in the Emerging Markets region. The guidance continues to include the effects of a comprehensive healthcare reform in Greece of DKK 100m, which is expected to impact all business areas.

Reported growth in DKK is expected to be ~6%, up from previously 5-6%, mainly due to developments in the USD/DKK exchange rate. The change is due to the upgraded guidance for organic revenue growth. Coloplast continues to expect an EBIT margin of 31%-32% at constant exchange rates and a reported EBIT margin of ~31% in DKK.

CONTACTS

Lina Danstrup

Senior Media Relations Manager, Corporate Communications

+45 49 11 26 07

dklina@coloplast.com

Ellen Bjurgert

Director, Investor Relations

+45 49 11 33 76

dkebj@coloplast.com 

Attachments

Vedhæftet fil 1: 2017_2018_Q2_PM_DK.pdf
Vedhæftet fil 2: 2017_2018_Q2_PM_ENG.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
12 jul
COLO-B
Kan se du har skrevet i min tidligere tråd skrev præcist det samme (link i hovedteksten). Siden er a..
2
12 jul
COLO-B
  Jeg skrev i maj (se Tidligere tråd ) at Coloplast måske ville bryde 4 års konsolidering og gå mod ..
2
12 jul
COLO-B
Realisten2: Jeg evaluere dag for dag. Som skrevet ovenfor virker markedet ikke særlig bekymret ved e..
1
12 jul
COLO-B
Arhh pas nu på at vi ikke bliver for sensitive. Der er blevet sagt det der var værre herinde og iøvr..
1
12 jul
COLO-B
Nu er prisdannelsen heldigvis markedets samlede mening og over de seneste måneder virker det til at ..
1
12 jul
COLO-B
Jeg fornemmer en halvsur mavefornemmelse ovre ved dig over årets stigning, men må indrømme at jeg ha..
1
12 jul
COLO-B
Coloplast har været plaget af nogle trælse sager, som såvidt jeg er orienteret, er kommet ud af syst..
1

Topdanmark/ABG: hæver kursmålet til 270 kr. fra 235 kr.

13-07-2018 14:23:25
Topdanmark får hævet sit kursmål til 270 kr. fra 235 kr. hos ABG Sundal Collier. Det fremgår af Bloomberg News.Opjusteringen af kursmålet ændrer ikke ved anbefalingen, som forbliver "sælg".Forsikringsaktien handles fredag 1 pct. højere i 310,20 kr. frem/ritzau/FINANS

Unibrew/CEO: Nøglefokus er nu på de opkøb vi har foretaget

13-07-2018 08:26:36
Om der er flere opkøb i vente fra Royal Unibrew vil topchefen Hans Savonije ikke oplyse, men han vil have fokus på de opkøb, der nu er foretaget senest med opkøbet af franske Etablissements Geyer Fréres for 660 mio. kr. Det siger han til Ritzau Finans. - Om der er flere opkøb i vente vil jeg ikke oplyse, siger han, og tilføjer:- Vi har en masse på vores tallerken nu. Så nu er fokus på, at de akti..

NKT taber ankesag om kartelbøde

12-07-2018 12:27:34
NKT og ti andre kabelproducenter har tabt en ankesag om en samlet kartelbøde på 302 mio. euro (2,25 mia. kr.), de blev idømt i 2014. Det skriver Bloomberg News.EU-Kommissionen kom dengang frem til, at de 11 kabelselskaber havde ageret som et kartel fra 1999 og godt ti år frem. NKT's andel af bøden var dog kun 3,9 mio. euro, svarende til cirka 29 mio. kr., mens Nexans og Prysmian fik de klart størs..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Coloplast B A/S 665,60 -0,7% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer  |  Cookie- og privatlivspolitik  |  Persondatapolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
15. juli 2018 21:31:09
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180712.1 - EUROWEB4 - 2018-07-15 21:31:09 - 2018-07-15 21:31:09 - 1 - Website: OKAY